Cite
Buist MR, Kenemans P, Vermorken JB, et al. Radioimmunotargeting in ovarian carcinoma patients with indium-111 labeled monoclonal antibody OV-TL 3 F(ab')2: pharmacokinetics, tissue distribution, and tumor imaging. Int J Gynecol Cancer. 1992;2(1):23-34doi: 10.1046/j.1525-1438.1992.02010023.x.
Buist, M. R., Kenemans, P., Vermorken, J. B., Golding, R. P., Burger, C. W., Den Hollander, W., Van Kamp, G. J., Van Lingen, A., Teule, G. J., Baak, J. P., & Roos, J. C. (1992). Radioimmunotargeting in ovarian carcinoma patients with indium-111 labeled monoclonal antibody OV-TL 3 F(ab')2: pharmacokinetics, tissue distribution, and tumor imaging. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2(1), 23-34. https://doi.org/10.1046/j.1525-1438.1992.02010023.x
Buist, M.R., et al. "Radioimmunotargeting in ovarian carcinoma patients with indium-111 labeled monoclonal antibody OV-TL 3 F(ab')2: pharmacokinetics, tissue distribution, and tumor imaging." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society vol. 2,1 (1992): 23-34. doi: https://doi.org/10.1046/j.1525-1438.1992.02010023.x
Buist MR, Kenemans P, Vermorken JB, Golding RP, Burger CW, Den Hollander W, Van Kamp GJ, Van Lingen A, Teule GJ, Baak JP, Roos JC. Radioimmunotargeting in ovarian carcinoma patients with indium-111 labeled monoclonal antibody OV-TL 3 F(ab')2: pharmacokinetics, tissue distribution, and tumor imaging. Int J Gynecol Cancer. 1992 Jan;2(1):23-34. doi: 10.1046/j.1525-1438.1992.02010023.x. PMID: 11576231.
Copy
Download .nbib